recast-jats-buildd8e1462159jitcJ Immunother CancerjitcJournal for ImmunoTherapy of CancerJ Immunother CancerJ Immunother Cancer2051-1426BMJ Publishing Group Ltdjitc-2019-000218corr110.1136/jitc-2019-000218corr134344798/jitc/9/8/1.1.atomCorrectionOpen accessSpecial collectionsOpen accessCorrection: CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells820212820211820211820219811© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.2021http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.special-featureunlocked

Martens AWJ, Janssen SR, Derks IAM, et al. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells. J Immunother Cancer 2020;8:e000218. doi: 10.1136/jitc-2019-000218

This paper has been updated since first published to update Figure 5I. One patient was removed from the figure since the patient originally labeled as chronic lymphocytic leukemia, has been recently re-diagnosed as indolent CD5 +mantle cell lymphoma.